GERON CORP Increase (Decrease) in Accounts Payable
GERON CORP (GERN) reported Increase (Decrease) in Accounts Payable of -$2.45 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-05
- GERON CORP increase (decrease) in accounts payable for the quarter ending 2026-06-30 was -$3.92M, a 2118.04% decline year-over-year.
- GERON CORP increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $1.46M.
- GERON CORP increase (decrease) in accounts payable for the quarter ending 2025-06-30 was $194.00K.
- GERON CORP increase (decrease) in accounts payable for the quarter ending 2025-03-31 was -$563.00K.
- GERON CORP increase (decrease) in accounts payable for fiscal 2025 was $2.66M, a 9.28% increase from fiscal 2024.
- GERON CORP increase (decrease) in accounts payable for fiscal 2024 was $2.44M.
- GERON CORP increase (decrease) in accounts payable for fiscal 2023 was -$4.03M, a 215.02% decline from fiscal 2022.
- GERON CORP increase (decrease) in accounts payable for fiscal 2022 was $3.50M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|
| 2026-06-30 | -$3.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$2.45M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $1.46M 10-Q · filed 2026-05-06 | ||
| 2025-12-31 | $2.66M 10-K · filed 2026-03-02 | ||
| 2025-06-30 | $194.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$369.00K 10-Q · filed 2026-08-05 | |
| 2025-03-31 | -$563.00K 10-Q · filed 2026-05-06 | ||
| 2024-12-31 | $2.44M 10-K · filed 2026-03-02 | ||
| 2023-12-31 | -$4.03M 10-K · filed 2026-03-02 | ||
| 2022-12-31 | $3.50M 10-K · filed 2025-02-27 | ||
| 2021-12-31 | -$232.00K 10-K · filed 2024-02-28 | ||
| 2020-12-31 | $5.73M 10-K · filed 2023-03-16 | ||
| 2019-12-31 | $199.00K 10-K · filed 2022-03-10 | ||
| 2018-12-31 | $479.00K 10-K · filed 2021-03-11 | ||
| 2017-12-31 | $278.00K 10-K · filed 2020-03-12 | ||
| 2016-12-31 | $65.00K 10-K · filed 2019-03-07 | ||
| 2015-12-31 | -$873.00K 10-K · filed 2018-03-16 | ||
| 2014-12-31 | -$364.00K 10-K · filed 2017-03-01 | ||
| 2013-12-31 | -$2.03M 10-K · filed 2016-03-10 | ||
| 2012-12-31 | $449.00K 10-K · filed 2015-03-11 | ||
| 2011-12-31 | -$482.00K 10-K · filed 2014-03-17 | ||
| 2010-12-31 | $1.29M 10-K · filed 2013-03-15 | ||
| 2009-12-31 | -$56.00K 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B |